Limitations of Molecular and Antigen Test Performance for SARS-CoV-2 in Symptomatic and Asymptomatic COVID-19 Contacts

Article activity feed

1. Version published to 10.1128/jcm.00187-22

   Jul 20, 2022
2. 

   ScreenIT

   Feb 10, 2022

   SciScore for 10.1101/2022.02.05.22270481: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	Consent: Study staff obtained informed consent from willing and eligible participants using a script administered either over the phone or in person. IRB: The study was approved by the Johns Hopkins School of Medicine Internal Review Board.
   Sex as a biological variable	not detected.
   Randomization	not detected.
   Blinding	At the time of test performance and interpretation, staff were blinded to results of other testing modalities and sample types.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Experimental Models: Cell Lines
   Sentences	Resources
   (14) Viral infectivity was assessed on VeroE6TMPRSS2 cells as previously described using infection media (IM; identical to CM …

   SciScore for 10.1101/2022.02.05.22270481: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	Consent: Study staff obtained informed consent from willing and eligible participants using a script administered either over the phone or in person. IRB: The study was approved by the Johns Hopkins School of Medicine Internal Review Board.
   Sex as a biological variable	not detected.
   Randomization	not detected.
   Blinding	At the time of test performance and interpretation, staff were blinded to results of other testing modalities and sample types.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Experimental Models: Cell Lines
   Sentences	Resources
   (14) Viral infectivity was assessed on VeroE6TMPRSS2 cells as previously described using infection media (IM; identical to CM except the FBS is reduced to 2.5%).(15) When a cytopathic effect was visible in >50% of cells in a given well, the supernatant was harvested.	VeroE6TMPRSS2 suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   Limitations include the possibility that other commercially available antigen tests may outperform the one chosen for use in this study, although direct comparisons of the Veritor antigen test used in this study has shown similar performance characteristics to others.(25, 36) Similarly, differences in the analytical sensitivity of SARS-CoV-2 test platforms may impact the results if this study were to be replicated using alternative SARS-CoV-2 NAT. Performance of the antigen tests was not performed as intended at the point of collection, which could reduce their sensitivity. Most of the positive cases were from unvaccinated persons prior to circulation of delta and omicron variants – as more vaccinated persons test positive for COVID, new data regarding the relationship between pretest probability of infection, test performance characteristics, SARS-CoV-2 variant, and culture positivity may be required. Data regarding timing of participant exposure to an individual with COVID was not available, which limits the ability to identify subgroups of close contacts with better or worse test performance. Ongoing SARS-CoV-2 transmission with increasingly contagious variants highlights the continued importance of widespread and accurate testing even as the pandemic approaches its third year. Our findings in a large cohort of close contacts demonstrate the limitations of cross-sectional antigen testing to exclude transmissibility, and standard NAT to diagnose COVID-19. Close contacts of ...

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
3. 

   Version published to 10.1101/2022.02.05.22270481 on medRxiv

   Feb 7, 2022